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INTRODUCTION
Metastatic breast cancer (MBC) remains a leading cause of cancer death in western countries. Despite advances in diagnosis and treatment, the median survival of women with MBC that is no longer hormonally responsive or is estrogen receptor (ER)-negative is 18-24 months, and fewer than 5% are alive and disease free at 5 years. [1] [2] [3] Throughout the 1980s and early 1990s, reports suggested that long-term disease-free survival (DFS) could be achieved with high-dose chemotherapy (HDC) using alkylating-agent combinations supported by autologous hematopoietic stem cell transplantation (AHSCT). [4] [5] [6] [7] By the mid-1990s, breast cancer (BC) had become the most common indication for AHSCT in North America and Europe. Phase II studies created positive expectations among physicians and their patients, to such an extent that HDC with AHSCT became widely used as a therapeutic option also outside the controlled trials. 8, 9 The use of PBSC as a source of progenitor cells, instead of BM for transplant, 10 significantly reduced the morbidity and mortality, related to HDC and allowed the utilization of this procedure outside specialized or academic centers. There followed a phase of disillusion after reports of some randomized studies not showing significant OS benefit of HDC [11] [12] [13] [14] [15] [16] and after a case of scientific misconduct. 17 The scene was prematurely set for the demise of HDC in BC and, in more recent years, the number of procedures has diminished and, in fact, abandoned by the vast majority of Centers.
Retrospective studies have shown that younger BC patients with limited tumor load or with highly sensitive disease may benefit from intensified chemotherapy. [18] [19] [20] [21] It comes out clearly from most of the prospective studies and from a large EBMT (European Group for Blood and Marrow Transplantation) retrospective analysis 22 that 15-30% of patients undergoing HDC after achieving CR from conventional treatments are longterm (45 years) disease-free survivors.
New information provided from phase III trials [23] [24] [25] suggests that HDC may still have a role in subgroups of patients with BC, both in the adjuvant setting and for metastatic disease mainly when risk factors and biological parameters are considered.
Recently meta-analyses obtained individual patient data from 15 adjuvant and 6 MBC randomized trials that compared HDC to a control therapy without stem-cell support. 26, 27 In both the settings, HDC achieved a statistically significant improvement in EFS but without a significant improvement in OS.
As a contribution to the field of HDC for MBC, we report here the results of this therapeutic approach in women treated in Italy between 1990 and 2005.
METHODS
The Italian Group of Bone Marrow and Hematopoietic Stem Cell Transplantation and Cellular Therapy (GITMO) was set up in 1987 to collect information regarding patients undergoing HDC in Italy and provide a point of meeting for physicians and nurses that deal with autologous and allogeneic transplantation. The increasing involvement of the Italian centers has allowed the creation of an association able to coordinate and to conduct national and international clinical researches, through numerous relationships of cooperation with local organizations and the EBMT.
GITMO centers are required to send patient data each year to the Central EBMT Database either directly, or through the GITMO itself. There are two levels of data: minimal essential data type A (MED A), which are compulsory and consider major items such as demographic data, disease classification, type of transplant outcomes and follow-up; and minimal essential data B (MED B) referring to items sent on a volunteer basis (type of conditioning or mobilization regimens, complications, number of cells transplanted, and so on).
According to EBMT and GITMO guidelines, the original and subsequent versions of the World Health Organization (WHO) criteria were adopted to define clinical response. 28 In patients with only bone metastases, extent of bone disease was characterized by number of lesions. Progressive disease was defined as new metastatic disease outside the bones, a 25% increase in the lytic bone metastases or a new lytic bone metastasis seen on radiological bone studies. 29 Menopausal status was defined according to international standards. 30 The primary outcome measure of the study was OS and PFS in patients with MBC undergoing HDC with AHSCT in Italy between 1990 and 2005. Secondary end-points were to value the mortality of the procedure and to correlate the effectiveness of such therapy to the clinical and biological characteristics of the patients.
Statistical analysis
Probabilities of TRM (that is, any death not related to the disease occurring within the first 100 days after graft), PFS and OS were calculated using the Kaplan-Meier product limit estimate. The log-rank test was used for comparisons of PFS and survival between groups. OS and PFS rates were measured from the date of transplant to the date of last follow-up or death and the date of progression, respectively.
RESULTS
Between 1 January 1990 and 31 December 2005, 588 patients with MBC receiving HDC and AHSCT in 36 Italian Centers were reported to the Registry. Additional information was requested and replies were received from the principal GITMO Centers, although not all provided data for the specific time points for follow-up nor for all questions relating to patients' characteristics. 173 cases (29%) with incomplete data set for OS and PFS have been excluded from the analysis; 415 were eligible for OS analysis and represent the body of this paper. Relevant patient characteristics are summarized on Table 1 .
The most of transplants were performed using PBSC (495%). HDC was given following a median of four cycles (range 1-8) of conventional dose chemotherapy including adriamycin and/or taxanes in the majority of patients. Time from the diagnosis of metastatic disease to transplant was 9 months (range 1-77) ( Table 1 ). TRM occurred in 11 patients (2.5%) overall and there were a total of two secondary malignancies (colorectal and ovarian cancer, respectively) and, at the time of writing, no hematological malignancies have been reported.
All high-dose conditioning regimens employed included alkylating agents. Mitoxantrone, in combination with an alkylating agent, was utilized in 48% of patients. The thiothepa/melphalan was the most frequently used schedule ( 37%), while melphalan/ With a median follow-up of 27 months (range 0-172), OS and PFS at 5 and 10 years in the whole population were 47/23 and 32/ 14%, respectively (Figures 1a and b) . 239 patients are alive with a median follow-up of 33 months (range 2-174). Menopausal status did not significantly impact on survival (P ¼ 0.06) (Figure 2a ) whereas a significant longer survival was observed among patients with hormone receptor positive (HR þ ) tumors (P ¼ 0.028) (Figure 2b ) and in patients without visceral metastasis (P ¼ 0.009). As expected, patients receiving HDC after obtaining a response to conventional cell transplantation had a significantly better OS compared with those receiving this therapy in stable disease (SD) or progressive disease (PD) (Po00001). Among patients transplanted in CR or PR, 54 and 37% were alive at 5 and 10 years, respectively (Figure 3 ). HDC with AHSCT was effective in producing a CR in 68 out of 333 patients (20.4%) for whom standard dose chemotherapy (SDC) failed to produce CR. In such a population, outcome did not differ significantly compared with patients transplanted in CR (10-year OS ¼ 33%) whereas patients never achieving CR by HDC had a poorer outcome, 5% of patients being alive at 10 years (Figures 4a and b) .
DISCUSSION
For the past decade, systemic treatment for high-risk primary BC and MBC has significantly advanced in terms of new therapeutic agents and new treatment delivery systems. The outcome for BC has also improved significantly compared with that for other solid tumors, especially in the adjuvant setting. However, we have yet to cure advanced BC, in particular, metastatic disease. 
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We report the long-term results of HDC with AHSCT in 415 patients with MBC from the Italian registry, and our results show that a sizable subgroup of patients survived 10 years (32%) and that 14% were free of disease at 10 years. The cohort of patients is one of the largest ever published for MBC. As it comes from a registry, many parameters are lacking and making conclusions is difficult, and the apparently favorable results after HDC could result entirely, or partially, from patient inclusion bias and whether that 29% patients with incomplete data set for survival have been excluded from the analysis. Although the data presented cannot deal with this problem as this is not a controlled study, the data are useful to hypothesize as to which subgroup of patients might benefit from intensive chemotherapy. Results of this retrospective analysis should be viewed considering that patients receiving HDC differ from the general population of patients with BC. Thus, differences observed between patients receiving transplantation and those who received SDC in historical data bases may result from selection biases. Unfortunately, the outcomes of prospective phase III studies, so far reported, 27 had been quite variable, this partially depending on their heterogeneity and the lack of sufficient numbers of patients to assess interventions with adequate statistical power. 31 Since the presentation of Berry's results, 27 the scientific community 32 has considered the argument for HDC with AHSCT in BC to be over owing to a lack of definite OS benefit. In the setting of MBC, as it is considered incurable, disease progression is almost inevitable. Any treatment that could delay the progression should also be considered significant. The metaanalysis 27 showed a benefit in PFS and this finding strongly suggests that there is a role for HDC in delaying disease progression. Therefore, when the treatment-related toxicity is within acceptable level, a benefit in EFS, which are often the primary endpoint in modern prospective studies, should not be ignored. 33 In such circumstances, retrospective analysis may contribute to understand whether a treatment modality may be valuable and worthy of further studies. 34 In our study, OS data seem to match favorably to reported results of SDC, 1-3 a significant number of patients being long-term overall and disease-free survivors.
Individual studies have suggested that age/menopausal status, hormone-receptor status or HER-2/neu expression, tumor load, and chemosensitivity may be predictive of the benefits of HDC. 35 Unfortunately, in our series, no sufficient data on HER-2 expression were available for a subset analysis.
The subgroup analysis demonstrating longer survival in patients with non-visceral disease and HR þ are of limited significance as these are established prognostic markers in MBC and do not represent predictive markers of increased benefit from HDC. 36 In our cohort of patients with MBC, women receiving HDC as consolidation therapy after achieving response to SDC had the best prognosis, confirming previous reports. 21, 22, 37 A significant proportion of such patients are long-term progression-free survivors. Importantly, HDC was effective in producing a CR in 20.4% of patients for whom SDC failed to produce CR; such patients having an outcome superimposable to patients transplanted in CR. Unfortunately, we do not have information available on the post-transplant therapy. This would contribute substantially to subsequent survival and assist in understanding the extent to which newer agents contributed to prolonged survival especially among patients diagnosed between 2000 and 2005. Median time from diagnosis of MBC to HDC with AHSCT is 9 months, certainly not long enough to benefit from currently available therapy. This is a limitation of the study but it is also true that at the time, when HDC was proposed, the new drugs were not available.
The GITMO Registry data show that HDC with AHSCT today is a safe procedure. TRM has significantly reduced over the years, possibly related to the use of PBSC and better supportive measures along with a widespread better knowledge of the whole procedure. Moreover, the overall low mortality rate in our series might also be related, in Italy, to the use of HDC regimens with a better toxicity profile as compared with early, that is, BCNUbased regimens, 4 mainly utilized in the US, which are associated with a high TRM. In clinical decision making, any potential benefit in recurrence or survival must be weighed against the greater toxicities of HDC. Individual studies have reported that quality of life (QoL) among HDC patients is lower, as expected, during treatment than among SDC patients. 38, 39 There is less agreement regarding QoL, once treatment is complete. Farquhar et al. 38 report that quality of life becomes comparable in the two groups over time while Marino et al. 39 utilizing a quality-adjusted survival analysis, concludes that HDC is, at least, as good as SDC in terms of quality-adjusted survival, and is significantly better for many reasonable variables of the weighting QoL coefficients.
In conclusion, our findings suggest that could be a role for HDC and AHSCT in delaying disease progression and possibly cure a subset of patients harboring chemosensitive tumors. Therefore, instead of simply giving up on a potential treatment modality, 40 it is more logical and practical to refine and improve this existing therapy in addition to developing new approaches in the clinical trial setting. 41 Improvement of treatment of MBC may well come, in the future, by integrating intensified CT, being per-se capable of remarkable and rapid tumor regression, with novel treatment strategies (that is, immunotherapy or target-specific therapy) for their potential to eliminate residual disease.
